FDA Fast Track: BioNTech mRNA cancer vaccine for advanced melanoma
- Can Cytokine Modulation Enhance the Efficacy of CAR-T Cell Therapy?
- What Are HIV-Related Cancers and How Can They Be Prevented?
- Metformin: From Diabetes Treatment to a New Approach for HIV Cure
- Advances in Research on HPV-Related Oropharyngeal Cancer and Immunotherapy
- Could mRNA Vaccines Be the Dawn of a New Era in Cancer Immunotherapy?
- Parkinson’s and Alzheimer’s Diseases May Originate in the Gut!
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA Fast Track: BioNTech mRNA cancer vaccine for advanced melanoma.
The mRNA cancer vaccine is here! FDA grants BioNTech Fast Track qualification for mRNA cancer vaccine for the treatment of advanced melanoma.
On November 19, 2021, mRNA vaccine giant BioNTech issued an announcement announcing that the US FDA has granted its mRNA cancer vaccine BNT111 fast track qualification .
BNT111 is an investigational cancer immunotherapy for the treatment of advanced melanoma.
It is one of the four product candidates of BioNTech’s FixVac platform. The platform uses a combination of tumor-associated antigens encoded by mRNA to trigger powerful and precise cancer Immune response to cancer treatment .
The BNT111 vaccine is currently undergoing phase 2 clinical trials for the treatment of PD-1 inhibitor refractory/relapsed unresectable stage III or IV melanoma, clinical trial number: NCT04526899.
It is reported that BNT111 encodes four tumor-associated antigens that appear in more than 90% of melanoma patients- NY-ESO-1 , MAGE-A3 , tyrosinase and TPTE , which can be prevented by combining with PD-1 inhibitors Depletion of T cells improves the prognosis of patients with advanced melanoma.
Fast Track aims to promote the development and review of new drugs and vaccines designed to treat or prevent serious diseases that may solve unmet medical needs.
The FDA’s approval this time is based on existing preclinical and clinical data. On July 29, 2020, BioNTech published the interim analysis of the Phase 1 clinical trial in Nature , showing that BNT111 has the potential to overcome the currently inoperable advanced melanin The limitations of the tumor.
BioNTech co-founder and chief medical officer Özlem Türeci said that BNT111’s fast track approval by the FDA demonstrates the potential of the FixVac platform.
With the support of the FDA, BioNTech will accelerate the further development of the BNT111 project to provide life-threatening and difficult-to-treat melanoma patients New treatment options.
Reference materials:
https://www.nature.com/articles/s41586-020-2537-9
https://investors.biontech.de/news-releases/news-release-details/biontech-receives-fda-fast-track-designation-its-fixvac
FDA Fast Track: BioNTech mRNA cancer vaccine for advanced melanoma
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
